The FDA released draft industry guidance for its pathway aimed at providing incentives to stimulate competition for branded drugs that have few or no generic counterparts in the marketplace. Separately, it also updated its “name and shame” list.
The FDA released draft industry guidance for its pathway aimed at providing incentives to stimulate competition for branded drugs that have few or no generic counterparts in the marketplace.
The draft guidance outlines the criteria and timing to designate a drug as a competitive generic, the process for submitting the request, the considerations for expedited development, actions the FDA might take to expedite development and review, and determining exclusivity for the generic.
A drug can move along the competitive generic therapies (CGT) pathway when there is not more than 1 approved drug in the active section of the Orange Book. The designation, set by Congress when it granted the FDA new authorities in the FDA Reauthorization Act of 2017, provides certain incentives for industry to develop generics for drugs lacking competition that have been designated as CGTs.
In a statement, FDA Commissioner Scott Gottlieb, MD, called it “a significant advancement in generic drug competition.” He also said that over the next year, additional policies to promote competition will be released, including for complex drugs.
To date, the FDA has granted more than 100 CGT designation requests, according to the FDA. Last year, between August and December, the FDA approved the first 5 abbreviated New Drug Applications (ANDAs) for generic drugs designated as CGTs.
The CGT pathway “is efficient and effective at promoting new competition. It’s also a key step in making safe and effective generic drugs available to patients quickly while helping to ensure there’s adequate competition in the market place, so patients have access to the treatments they need,” Gottlieb said.
The FDA said the designation has a number of benefits, such as:
Separately, the FDA also updated its list of companies that have restricted access to samples of small-molecule drugs for testing through the use of Risk Evaluation and Mitigation Strategies (REMS) programs or limited distribution of their products.
The so-called “name and shame” list was first unveiled in May 2018. According to the FDA, there have been 9 new inquiries listed or submitted since the list fist published.
In addition, there have been 3 new safety determination letters issued, bringing the total to 24, and 1 additional drug product (tolvaptan, sold as Jynarque) listed which had a REMS Elements to Assure Safe Use impacting distribution to potential generic competitors. Tolvaptan is used to treat low blood sodium.
The number of drug products listed rose from 51 to 54. Besides tolvaptan, the others were the antiparasite drug pyrimethamine (Daraprim) and tiopronin (Thiola), which is used to treat cystinauria.
REMS programs, which manage potential risks of a drug, have come under scrutiny as potential avenues for anticompetitive behavior in the marketplace. Some stakeholders warn that REMS programs are used by some drug makers to improperly withhold samples of products for testing by biosimilar or generic drug developers, even in cases in which the FDA has informed a drug company in writing that it will not consider provision of samples to be a violation of a REMS program.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
FDA Green Lights Second Tocilizumab Biosimilar
March 7th 2024The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.
Samsung Bioepis Announces New Biosimilar Partnership, Regulatory Updates
February 27th 2024Samsung Bioepis provided multiple updates on its biosimilar projects, including a new partnership for its aflibercept biosimilar candidate as well as regulatory news in the European Union and Republic of Korea.